Ultimately, this work supports GLP-1 RA usage beyond metabolic indications in select urologic patients, such as those with treatment-resistant OAB, co-existing obesity, or heightened UTI risk. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.